Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study


Por: Mercader, SM, Garcia-Bustos, V, Moral, PM, Buenaventura, CM, Vergara, EE, Bosch, MCM, Balastegui-Martín, H, Maycas, SG, Amores, MG, Sanz, NG, Palazón, ME, Mulet, MM, Carrasco, IC, López, A, Ruiz, CDH, Ruiz-López, L, Guzmán, RG and Cabañero-Navalon, MD

Publicada: 15 ago 2025
Resumen:
Background/Objectives: Subcutaneous immunoglobulin (SCIg) is a well-established alternative to intravenous immunoglobulin (IVIg) in patients with primary (PID) and secondary immunodeficiency (SID), with demonstrated benefits in safety and quality of life. However, its implementation remains limited in parts of Southern Europe, partly due to frequent local adverse reactions (LARs), which, despite being mild, can affect adherence and clinician confidence. This study aimed to identify clinical, anatomical, psychosocial, and geographical factors associated with LARs and to develop an exploratory model for individualized risk estimation. Methods: We conducted a retrospective, multicenter observational study in eight Spanish hospitals using data from the GEIE Registry. Patients aged >= 14 years with PID or SID receiving SCIg for >= 1 month were included. Demographic, clinical, anatomical, and psychosocial variables were collected. A multivariable logistic regression model was built to identify independent predictors of LARs and internally validated using bootstrap resampling (500 iterations). A nomogram was constructed for personalized risk prediction. Results: Among 223 included patients, 73.1% reported LARs, primarily swelling, pruritus, and rash. Independent predictors included smaller abdominal perimeter (OR 0.955, p < 0.001), history of skin disease (OR 2.75, p = 0.044), greater distance to hospital (OR 1.01, p = 0.050), and absence of anxiety (OR 0.089, p = 0.001). Model discrimination was good (AUC 0.801), with minimal optimism after internal validation (validated AUC 0.788). Conclusions: LARs are common among patients receiving SCIg and could be influenced by anatomical, dermatological, psychological, and geographical factors. This exploratory multicenter study underscores the clinical relevance of these factors and may guide more personalized and safer use of SCIg.

Filiaciones:
Mercader, SM:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

Garcia-Bustos, V:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

 Hlth Res Inst La Fe, Severe Infect Res Grp, Valencia 46026, Spain

Moral, PM:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

 Hlth Res Inst La Fe, Res Grp Chron Dis & HIV Infect, Valencia 46026, Spain

Buenaventura, CM:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

Vergara, EE:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

Bosch, MCM:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

Balastegui-Martín, H:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

 Hlth Res Inst La Fe, Res Grp Chron Dis & HIV Infect, Valencia 46026, Spain

Maycas, SG:
 Vall dHebron Univ Hosp, Pediat Infect Dis & Immunodeficiencies Unit, Barcelona 08035, Spain

 Vall dHebron Inst Recerca, Infect & Immun Pediat Patients Res Grp, Barcelona 08035, Spain

Amores, MG:
 Vall dHebron Inst Recerca, Infect & Immun Pediat Patients Res Grp, Barcelona 08035, Spain

Sanz, NG:
 Vall dHebron Inst Recerca, Infect & Immun Pediat Patients Res Grp, Barcelona 08035, Spain

Palazón, ME:
 Gregorio Maranon Gen Univ Hosp, Area Immunol, Multidisciplinary Day Hosp, Madrid 28007, Spain

Mulet, MM:
 Gregorio Maranon Gen Univ Hosp, Area Immunol, Multidisciplinary Day Hosp, Madrid 28007, Spain

Carrasco, IC:
 Reina Sofia Univ Hosp, Immunol Day Hosp Unit, Cordoba 14004, Spain

López, A:
 La Paz Univ Hosp, Oncohematol Day Hosp, Madrid 28046, Spain

Ruiz, CDH:
 Doctor Negrin Univ Hosp Gran Canaria, Internal Med Day Hosp, Gran Canaria 35010, Spain

:
 St Joan de Deu Hosp, Pediat Allergy & Clin Immunol Dept, Clin Immunol & Primary Immunodeficiencies Unit, Barcelona 08950, Spain

Guzmán, RG:
 Son Espases Univ Hosp, Day Hosp, Palma De Mallorca 07120, Spain

Cabañero-Navalon, MD:
 Univ & Polytech Hosp La Fe, Dept Internal Med, Primary Immunodeficiencies Unit, Valencia 46026, Spain

 Hlth Res Inst La Fe, Res Grp Chron Dis & HIV Infect, Valencia 46026, Spain
ISSN: 22279059





Biomedicines
Editorial
MDPI, MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 13 Número: 8
Páginas:
WOS Id: 001559758900001
ID de PubMed: 40868242
imagen Green Submitted, gold

MÉTRICAS